Research programme: antimicrobial therapies - NovaBiotics

Drug Profile

Research programme: antimicrobial therapies - NovaBiotics

Alternative Names: Novamycin; Novarifyn; NP 339; NP 432; NP 525

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NovaBiotics
  • Class Amino acids peptides and proteins; Peptides; Peptidomimetics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Methicillin-resistant Staphylococcus aureus infections; Mycoses; Pseudomonal infections
  • No development reported Acne

Most Recent Events

  • 03 Jul 2017 NP 432 is still in preclinical development for Clostridium infections and Pseudomonas infections in United Kingdom (Topical, Inhalation, Parenteral) (NovaBiotics pipeline, July 2017)
  • 03 Jul 2017 Preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections is ongoing in United Kingdom
  • 22 Apr 2017 Antimicrobial data from a preclinical study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top